2018 - Member of the National Academy of Medicine (NAM)
Member of the Association of American Physicians
Susan M. Domchek mainly investigates Breast cancer, Internal medicine, Cancer, Oncology and Gynecology. In her research on the topic of Breast cancer, Estrogen receptor is strongly related with Gene mutation. Her research integrates issues of Germline mutation, Surgery and Pathology in her study of Internal medicine.
Her Cancer research incorporates themes from Genetic testing, Cancer research and Bioinformatics. The various areas that Susan M. Domchek examines in her Oncology study include Olaparib, Tolerability, Metastatic breast cancer, Case-control study and Prostate cancer. The Gynecology study combines topics in areas such as Male breast cancer, Epidemiology, Obstetrics, Prospective cohort study and Cancer prevention.
Her scientific interests lie mostly in Breast cancer, Internal medicine, Oncology, Cancer and Ovarian cancer. Her Breast cancer research incorporates elements of Cancer research, Gynecology, Family history and Single-nucleotide polymorphism. Her study in Gynecology is interdisciplinary in nature, drawing from both Risk factor and Obstetrics.
The concepts of her Internal medicine study are interwoven with issues in Germline mutation and Olaparib. Her Oncology research integrates issues from PARP inhibitor, Chemotherapy, Gene mutation and Hazard ratio. Her Cancer study integrates concerns from other disciplines, such as CHEK2, Prospective cohort study, Odds ratio and Penetrance.
Her primary scientific interests are in Internal medicine, Oncology, Breast cancer, Cancer and Genetic testing. The Internal medicine study combines topics in areas such as Polygenic risk score, Olaparib and Cancer susceptibility. Her work is dedicated to discovering how Oncology, Germline are connected with Somatic cell and other disciplines.
She has researched Breast cancer in several fields, including CHEK2, Ejection fraction, Family history and Gene mutation. Susan M. Domchek interconnects Germline mutation, Li–Fraumeni syndrome and Proportional hazards model in the investigation of issues within Cancer. Her Genetic testing study combines topics in areas such as Usual care, Randomized controlled trial, MEDLINE, Bioinformatics and Genetic counseling.
The scientist’s investigation covers issues in Internal medicine, Oncology, Breast cancer, Cancer and Olaparib. Her studies deal with areas such as Random assignment and Anxiety as well as Internal medicine. The various areas that Susan M. Domchek examines in her Oncology study include Progressive disease, Chemotherapy, Ovarian cancer, Prospective cohort study and Complex segregation analysis.
She is studying Cancer Family, which is a component of Breast cancer. Her Cancer study incorporates themes from Germline mutation, Computational biology and Proportional hazards model. Her work carried out in the field of Olaparib brings together such families of science as Cancer research, Metastatic breast cancer, PARP inhibitor and Durvalumab.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson;Seock Ah Im;Elżbieta Senkus;Binghe Xu.
The New England Journal of Medicine (2017)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
Andrew Tutt;Mark Robson;Judy E Garber;Susan M Domchek.
The Lancet (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer
A Tutt;M Robson;J E Garber;S M Domchek.
The Lancet (2010)
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Bella Kaufman;Ronnie Shapira-Frommer;Rita K. Schmutzler;M. William Audeh.
Journal of Clinical Oncology (2015)
Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality
Susan M. Domchek;Tara M. Friebel;Christian F. Singer;D. Gareth Evans.
Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers
Timothy R. Rebbeck;Noah D. Kauff;Susan M. Domchek.
Journal of the National Cancer Institute (2009)
Breast-Cancer Risk in Families with Mutations in PALB2
A. C. Antoniou;S. Casadei;T. Heikkinen;D. Barrowdale.
The New England Journal of Medicine (2014)
Gene-Panel Sequencing and the Prediction of Breast-Cancer Risk
Douglas Frederick Easton;Paul David Pharoah;Antonis C. Antoniou;Marc Derek Tischkowitz.
The New England Journal of Medicine (2015)
American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility
Mark E. Robson;Mark E. Robson;Angela R. Bradbury;Banu K Arun;Susan M. Domchek.
Journal of Clinical Oncology (2010)
Risk-Reducing Salpingo-Oophorectomy for the Prevention of BRCA1- and BRCA2-Associated Breast and Gynecologic Cancer: A Multicenter, Prospective Study
Noah D. Kauff;Susan M. Domchek;Tara M. Friebel;Mark E. Robson.
Journal of Clinical Oncology (2008)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: